{
 "disease": "gallbladder-cancer",
 "label": "Gallbladder cancer",
 "url": "https://usebiotransfer.org/disease/gallbladder-cancer/",
 "built": "2026-09-16",
 "facts_hash": {
  "answers": "4da2c5e89822",
  "targets": "903af2ea1077"
 },
 "sources": {
  "targets": "Open Targets Platform GraphQL API v4",
  "trials": "ClinicalTrials.gov API v2"
 },
 "retrieved": {
  "targets": "2026-09-16",
  "trials": "2026-09-16"
 },
 "query": {
  "endpoint": "https://clinicaltrials.gov/api/v2/studies",
  "shape": "query.cond=<disease>&query.intr=<term>&pageSize=200",
  "active_statuses": [
   "ACTIVE_NOT_RECRUITING",
   "ENROLLING_BY_INVITATION",
   "NOT_YET_RECRUITING",
   "RECRUITING"
  ],
  "dedup": "by NCT id across synonyms",
  "study_types": "interventional counted in headline; observational reported separately",
  "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search"
 },
 "targets": [
  {
   "symbol": "ERBB2",
   "ensembl": "ENSG00000141736",
   "n_drug_entries": 48,
   "n_distinct_drugs": 45,
   "drugs": {
    "AC-480": "PHASE_2",
    "AEE-788": "PHASE_1_2",
    "AFATINIB": "APPROVAL",
    "AFATINIB DIMALEATE": "APPROVAL",
    "ALLITINIB": "PHASE_1",
    "ANVATABART OPADOTIN": "PHASE_2_3",
    "AV-412": "PHASE_1",
    "BMS-690514": "PHASE_2",
    "CANERTINIB": "PHASE_2",
    "CP-724714": "PHASE_2",
    "CUDC-101": "PHASE_1",
    "DACOMITINIB": "APPROVAL",
    "DISITAMAB VEDOTIN": "PHASE_3",
    "ERTUMAXOMAB": "PHASE_2",
    "GANCOTAMAB": "PHASE_2_3",
    "HEMAY-022": "PHASE_3",
    "JNJ-26483327": "PHASE_1",
    "KBP5209": "PHASE_1",
    "KN-026": "PHASE_3",
    "LAPATINIB": "APPROVAL",
    "LAPATINIB DITOSYLATE": "APPROVAL",
    "MARGETUXIMAB": "APPROVAL",
    "MASOPROCOL": "APPROVAL",
    "MM-111": "PHASE_2",
    "MUBRITINIB": "PHASE_1",
    "NERATINIB": "APPROVAL",
    "PERTUZUMAB": "APPROVAL",
    "POZIOTINIB": "PHASE_3",
    "PYROTINIB": "PHASE_3",
    "S-222611": "PHASE_1",
    "SAPITINIB": "PHASE_2",
    "TAK-285": "PHASE_1",
    "TARLOXOTINIB": "PHASE_2",
    "TESEVATINIB": "PHASE_3",
    "TRASTUZUMAB": "APPROVAL",
    "TRASTUZUMAB BOTIDOTIN": "PHASE_3",
    "TRASTUZUMAB DERUXTECAN": "APPROVAL",
    "TRASTUZUMAB DUOCARMAZINE": "APPROVAL",
    "TRASTUZUMAB EMTANSINE": "APPROVAL",
    "TUCATINIB": "APPROVAL",
    "TUXOBERTINIB": "PHASE_1_2",
    "VANDETANIB": "APPROVAL",
    "VARLITINIB": "PHASE_2_3",
    "ZANIDATAMAB": "APPROVAL",
    "ZENOCUTUZUMAB": "APPROVAL"
   },
   "approved": [
    "AFATINIB",
    "AFATINIB DIMALEATE",
    "DACOMITINIB",
    "LAPATINIB",
    "LAPATINIB DITOSYLATE",
    "MARGETUXIMAB",
    "MASOPROCOL",
    "NERATINIB",
    "PERTUZUMAB",
    "TRASTUZUMAB",
    "TRASTUZUMAB DERUXTECAN",
    "TRASTUZUMAB DUOCARMAZINE",
    "TRASTUZUMAB EMTANSINE",
    "TUCATINIB",
    "VANDETANIB",
    "ZANIDATAMAB",
    "ZENOCUTUZUMAB"
   ],
   "n_approved": 17,
   "approved_for": {
    "AFATINIB": [
     "non-small cell lung carcinoma"
    ],
    "AFATINIB DIMALEATE": [
     "non-small cell lung carcinoma"
    ],
    "DACOMITINIB": [
     "non-small cell lung carcinoma"
    ],
    "LAPATINIB": [
     "breast cancer"
    ],
    "LAPATINIB DITOSYLATE": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "MARGETUXIMAB": [
     "HER2 positive breast carcinoma",
     "breast cancer"
    ],
    "MASOPROCOL": [
     "prostate cancer"
    ],
    "NERATINIB": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "PERTUZUMAB": [
     "breast cancer",
     "breast carcinoma",
     "breast neoplasm"
    ],
    "TRASTUZUMAB": [
     "breast cancer",
     "breast carcinoma",
     "gastric cancer",
     "gastric neoplasm",
     "breast neoplasm"
    ],
    "TRASTUZUMAB DERUXTECAN": [
     "breast cancer",
     "HER2 positive breast carcinoma",
     "breast neoplasm"
    ],
    "TRASTUZUMAB DUOCARMAZINE": [],
    "TRASTUZUMAB EMTANSINE": [
     "breast cancer",
     "breast carcinoma",
     "breast neoplasm"
    ],
    "TUCATINIB": [
     "HER2 positive breast carcinoma",
     "metastasis",
     "breast neoplasm",
     "breast cancer",
     "colorectal carcinoma",
     "breast carcinoma"
    ],
    "VANDETANIB": [
     "thyroid gland carcinoma",
     "medullary thyroid gland carcinoma",
     "thyroid tumor"
    ],
    "ZANIDATAMAB": [
     "biliary tract neoplasm"
    ],
    "ZENOCUTUZUMAB": [
     "non-small cell lung carcinoma",
     "pancreatic neoplasm"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "TP53",
   "ensembl": "ENSG00000141510",
   "n_drug_entries": 9,
   "n_distinct_drugs": 8,
   "drugs": {
    "ALRIZOMADLIN": "PHASE_2",
    "CENERSEN": "PHASE_2",
    "CONTUSUGENE LADENOVEC": "PHASE_3",
    "EPRENETAPOPT": "PHASE_3",
    "IDASANUTLIN": "PHASE_3",
    "NAVTEMADLIN": "PHASE_3",
    "SIREMADLIN": "PHASE_2",
    "TEPRASIRAN": "PHASE_3"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "KRAS",
   "ensembl": "ENSG00000133703",
   "n_drug_entries": 3,
   "n_distinct_drugs": 3,
   "drugs": {
    "ADAGRASIB": "APPROVAL",
    "SALIRASIB": "PHASE_2",
    "SOTORASIB": "APPROVAL"
   },
   "approved": [
    "ADAGRASIB",
    "SOTORASIB"
   ],
   "n_approved": 2,
   "approved_for": {
    "ADAGRASIB": [
     "non-small cell lung carcinoma"
    ],
    "SOTORASIB": [
     "non-small cell lung carcinoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "PIK3CA",
   "ensembl": "ENSG00000121879",
   "n_drug_entries": 32,
   "n_distinct_drugs": 31,
   "drugs": {
    "ALPELISIB": "APPROVAL",
    "APITOLISIB": "PHASE_2",
    "AZD-6482": "UNKNOWN",
    "BAY-1082439": "PHASE_1",
    "BGT-226": "PHASE_1_2",
    "BUPARLISIB": "PHASE_3",
    "COPANLISIB": "APPROVAL",
    "DACTOLISIB": "PHASE_3",
    "DS-7423": "PHASE_1",
    "FIMEPINOSTAT": "PHASE_2",
    "GEDATOLISIB": "PHASE_3",
    "GSK-1059615": "PHASE_1",
    "INAVOLISIB": "APPROVAL",
    "IZORLISIB": "PHASE_1_2",
    "OMIPALISIB": "PHASE_1",
    "PANULISIB": "PHASE_1",
    "PAXALISIB": "PHASE_2_3",
    "PF-04691502": "PHASE_2",
    "PICTILISIB": "PHASE_2",
    "PILARALISIB": "PHASE_2",
    "PKI-179": "PHASE_1",
    "RECILISIB": "PHASE_1",
    "SAMOTOLISIB": "PHASE_2",
    "SERABELISIB": "PHASE_2",
    "SF-1126": "PHASE_2",
    "SONOLISIB": "PHASE_2",
    "TASELISIB": "PHASE_3",
    "VOXTALISIB": "PHASE_2",
    "VS-5584": "PHASE_1",
    "WX-037": "PHASE_1",
    "ZSTK-474": "PHASE_1"
   },
   "approved": [
    "ALPELISIB",
    "COPANLISIB",
    "INAVOLISIB"
   ],
   "n_approved": 3,
   "approved_for": {
    "ALPELISIB": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "COPANLISIB": [
     "follicular lymphoma",
     "non-Hodgkin lymphoma",
     "neoplasm of mature B-cells"
    ],
    "INAVOLISIB": [
     "breast neoplasm"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "GO CC med conf"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "CDKN2A",
   "ensembl": "ENSG00000147889",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": []
  },
  {
   "symbol": "ARID1A",
   "ensembl": "ENSG00000117713",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "ERBB3",
   "ensembl": "ENSG00000065361",
   "n_drug_entries": 17,
   "n_distinct_drugs": 17,
   "drugs": {
    "AMG-888": "PHASE_1",
    "AV-203": "PHASE_1",
    "CDX-3379": "PHASE_2",
    "DULIGOTUZUMAB": "PHASE_2",
    "ELGEMTUMAB": "PHASE_1_2",
    "ISTIRATUMAB": "PHASE_2",
    "KBP5209": "PHASE_1",
    "LUMRETUZUMAB": "PHASE_1_2",
    "MM-111": "PHASE_2",
    "PATRITUMAB": "PHASE_3",
    "PATRITUMAB DERUXTECAN": "APPROVAL",
    "POZIOTINIB": "PHASE_3",
    "SAPITINIB": "PHASE_2",
    "SERIBANTUMAB": "PHASE_2",
    "TARLOXOTINIB": "PHASE_2",
    "VANDETANIB": "APPROVAL",
    "ZENOCUTUZUMAB": "APPROVAL"
   },
   "approved": [
    "PATRITUMAB DERUXTECAN",
    "VANDETANIB",
    "ZENOCUTUZUMAB"
   ],
   "n_approved": 3,
   "approved_for": {
    "PATRITUMAB DERUXTECAN": [],
    "VANDETANIB": [
     "thyroid gland carcinoma",
     "medullary thyroid gland carcinoma",
     "thyroid tumor"
    ],
    "ZENOCUTUZUMAB": [
     "non-small cell lung carcinoma",
     "pancreatic neoplasm"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "EGFR",
   "ensembl": "ENSG00000146648",
   "n_drug_entries": 82,
   "n_distinct_drugs": 74,
   "drugs": {
    "ABIVERTINIB": "PHASE_3",
    "AC-480": "PHASE_2",
    "AEE-788": "PHASE_1_2",
    "AFATINIB": "APPROVAL",
    "AFATINIB DIMALEATE": "APPROVAL",
    "ALLITINIB": "PHASE_1",
    "AMIVANTAMAB": "APPROVAL",
    "AUMOLERTINIB": "APPROVAL",
    "AV-412": "PHASE_1",
    "AZD-3759": "PHASE_2_3",
    "AZD-4769": "PHASE_1",
    "BAFISONTAMAB": "PHASE_2",
    "BMS-690514": "PHASE_2",
    "BRIGATINIB": "APPROVAL",
    "CANERTINIB": "PHASE_2",
    "CEP-32496": "PHASE_1_2",
    "CETUXIMAB": "APPROVAL",
    "CETUXIMAB SAROTALOCAN": "APPROVAL",
    "CLN-081": "PHASE_3",
    "CUDC-101": "PHASE_1",
    "DACOMITINIB": "APPROVAL",
    "DEPATUXIZUMAB": "PHASE_2",
    "DEPATUXIZUMAB MAFODOTIN": "PHASE_3",
    "DULIGOTUZUMAB": "PHASE_2",
    "EPITINIB": "PHASE_1",
    "ERLOTINIB": "APPROVAL",
    "FALNIDAMOL": "PHASE_1",
    "FIRMONERTINIB": "PHASE_3",
    "FUTUXIMAB": "PHASE_3",
    "GC1118": "PHASE_2",
    "GEFITINIB": "APPROVAL",
    "ICOTINIB": "APPROVAL",
    "IMGATUZUMAB": "PHASE_2",
    "JNJ-26483327": "PHASE_1",
    "KBP5209": "PHASE_1",
    "LAPATINIB": "APPROVAL",
    "LAPATINIB DITOSYLATE": "APPROVAL",
    "LAZERTINIB": "APPROVAL",
    "LOSATUXIZUMAB VEDOTIN": "PHASE_1",
    "MAB-425": "UNKNOWN",
    "MATUZUMAB": "PHASE_2",
    "MAVELERTINIB": "PHASE_1_2",
    "MDX-447": "PHASE_1",
    "MOBOCERTINIB": "APPROVAL",
    "MODOTUXIMAB": "PHASE_2",
    "NAQUOTINIB": "PHASE_3",
    "NAZARTINIB": "PHASE_3",
    "NECITUMUMAB": "APPROVAL",
    "NERATINIB": "APPROVAL",
    "NIMOTUZUMAB": "APPROVAL",
    "OLMUTINIB": "APPROVAL",
    "OSIMERTINIB": "APPROVAL",
    "PANITUMUMAB": "APPROVAL",
    "PELITINIB": "PHASE_2",
    "PF-06459988": "PHASE_2",
    "PIMURUTAMAB": "PHASE_2_3",
    "PKI-166": "PHASE_2",
    "POZIOTINIB": "PHASE_3",
    "PYROTINIB": "PHASE_3",
    "RINDOPEPIMUT": "PHASE_3",
    "ROCILETINIB": "APPROVAL",
    "RUSERONTINIB": "PHASE_3",
    "S-222611": "PHASE_1",
    "SAPITINIB": "PHASE_2",
    "SIMOTINIB": "PHASE_1",
    "TAK-285": "PHASE_1",
    "TARLOXOTINIB": "PHASE_2",
    "TESEVATINIB": "PHASE_3",
    "THELIATINIB": "PHASE_1",
    "TOMUZOTUXIMAB": "PHASE_2",
    "TUXOBERTINIB": "PHASE_1_2",
    "VANDETANIB": "APPROVAL",
    "VARLITINIB": "PHASE_2_3",
    "ZALUTUMUMAB": "PHASE_3"
   },
   "approved": [
    "AFATINIB",
    "AFATINIB DIMALEATE",
    "AMIVANTAMAB",
    "AUMOLERTINIB",
    "BRIGATINIB",
    "CETUXIMAB",
    "CETUXIMAB SAROTALOCAN",
    "DACOMITINIB",
    "ERLOTINIB",
    "GEFITINIB",
    "ICOTINIB",
    "LAPATINIB",
    "LAPATINIB DITOSYLATE",
    "LAZERTINIB",
    "MOBOCERTINIB",
    "NECITUMUMAB",
    "NERATINIB",
    "NIMOTUZUMAB",
    "OLMUTINIB",
    "OSIMERTINIB",
    "PANITUMUMAB",
    "ROCILETINIB",
    "VANDETANIB"
   ],
   "n_approved": 23,
   "approved_for": {
    "AFATINIB": [
     "non-small cell lung carcinoma"
    ],
    "AFATINIB DIMALEATE": [
     "non-small cell lung carcinoma"
    ],
    "AMIVANTAMAB": [
     "non-small cell lung carcinoma"
    ],
    "AUMOLERTINIB": [
     "non-small cell lung carcinoma"
    ],
    "BRIGATINIB": [
     "non-small cell lung carcinoma",
     "anaplastic large cell lymphoma"
    ],
    "CETUXIMAB": [
     "malignant tumor of neck",
     "squamous cell carcinoma",
     "colorectal adenocarcinoma",
     "colorectal carcinoma",
     "colorectal cancer",
     "head and neck neoplasm",
     "colorectal neoplasm"
    ],
    "CETUXIMAB SAROTALOCAN": [
     "head and neck cancer"
    ],
    "DACOMITINIB": [
     "non-small cell lung carcinoma"
    ],
    "ERLOTINIB": [
     "non-small cell lung carcinoma",
     "pancreatic neoplasm"
    ],
    "GEFITINIB": [
     "non-small cell lung carcinoma",
     "head and neck squamous cell carcinoma"
    ],
    "ICOTINIB": [],
    "LAPATINIB": [
     "breast cancer"
    ],
    "LAPATINIB DITOSYLATE": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "LAZERTINIB": [
     "non-small cell lung carcinoma"
    ],
    "MOBOCERTINIB": [
     "non-small cell lung carcinoma"
    ],
    "NECITUMUMAB": [
     "non-small cell lung carcinoma",
     "colorectal cancer",
     "non-small cell squamous lung carcinoma"
    ],
    "NERATINIB": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "NIMOTUZUMAB": [
     "head and neck cancer"
    ],
    "OLMUTINIB": [],
    "OSIMERTINIB": [
     "non-small cell lung carcinoma"
    ],
    "PANITUMUMAB": [
     "colorectal cancer",
     "colorectal adenocarcinoma",
     "colorectal neoplasm"
    ],
    "ROCILETINIB": [],
    "VANDETANIB": [
     "thyroid gland carcinoma",
     "medullary thyroid gland carcinoma",
     "thyroid tumor"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "CTNNB1",
   "ensembl": "ENSG00000168036",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "PRI-724": "PHASE_2"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "SMAD4",
   "ensembl": "ENSG00000141646",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "FGFR2",
   "ensembl": "ENSG00000066468",
   "n_drug_entries": 27,
   "n_distinct_drugs": 26,
   "drugs": {
    "APRUTUMAB IXADOTIN": "PHASE_1",
    "BEMARITUZUMAB": "PHASE_3",
    "BRIVANIB": "PHASE_3",
    "BRIVANIB ALANINATE": "PHASE_3",
    "DERAZANTINIB": "PHASE_3",
    "E-7090": "APPROVAL",
    "ENMD-981693": "PHASE_2",
    "ERDAFITINIB": "APPROVAL",
    "FEXAGRATINIB": "PHASE_2",
    "FGFR INHIBITOR DEBIO 1347": "PHASE_2",
    "FUTIBATINIB": "APPROVAL",
    "HMPL-453": "PHASE_2",
    "INFIGRATINIB": "APPROVAL",
    "LUCITANIB": "PHASE_3",
    "LY-2874455": "PHASE_2",
    "NINTEDANIB": "APPROVAL",
    "NINTEDANIB ESYLATE": "APPROVAL",
    "ORANTINIB": "PHASE_3",
    "PALIFERMIN": "APPROVAL",
    "PEMIGATINIB": "APPROVAL",
    "REGORAFENIB": "APPROVAL",
    "RG-1530": "PHASE_1",
    "ROGARATINIB": "PHASE_2_3",
    "TG100-801": "PHASE_2",
    "TRAFERMIN": "APPROVAL",
    "XL-999": "PHASE_2"
   },
   "approved": [
    "E-7090",
    "ERDAFITINIB",
    "FUTIBATINIB",
    "INFIGRATINIB",
    "NINTEDANIB",
    "NINTEDANIB ESYLATE",
    "PALIFERMIN",
    "PEMIGATINIB",
    "REGORAFENIB",
    "TRAFERMIN"
   ],
   "n_approved": 10,
   "approved_for": {
    "E-7090": [
     "biliary tract cancer"
    ],
    "ERDAFITINIB": [
     "urothelial carcinoma",
     "urinary bladder carcinoma"
    ],
    "FUTIBATINIB": [
     "biliary tract cancer",
     "intrahepatic cholangiocarcinoma",
     "cholangiocarcinoma"
    ],
    "INFIGRATINIB": [
     "cholangiocarcinoma"
    ],
    "NINTEDANIB": [
     "idiopathic pulmonary fibrosis",
     "colorectal cancer",
     "interstitial lung disease",
     "systemic sclerosis",
     "pulmonary fibrosis"
    ],
    "NINTEDANIB ESYLATE": [
     "idiopathic pulmonary fibrosis",
     "systemic sclerosis",
     "non-small cell lung carcinoma",
     "Interstitial pneumonitis"
    ],
    "PALIFERMIN": [
     "oral mucositis",
     "mucositis"
    ],
    "PEMIGATINIB": [
     "biliary tract cancer",
     "cholangiocarcinoma"
    ],
    "REGORAFENIB": [
     "colorectal cancer",
     "metastatic colorectal cancer",
     "colorectal neoplasm"
    ],
    "TRAFERMIN": [
     "periodontitis",
     "Skin ulcer"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  },
  {
   "symbol": "IDH1",
   "ensembl": "ENSG00000138413",
   "n_drug_entries": 8,
   "n_distinct_drugs": 7,
   "drugs": {
    "BAY1436032": "PHASE_1",
    "DS-1001B": "PHASE_2",
    "IDH305": "PHASE_2",
    "IVOSIDENIB": "APPROVAL",
    "OLUTASIDENIB": "APPROVAL",
    "SAFUSIDENIB": "PHASE_3",
    "VORASIDENIB": "APPROVAL"
   },
   "approved": [
    "IVOSIDENIB",
    "OLUTASIDENIB",
    "VORASIDENIB"
   ],
   "n_approved": 3,
   "approved_for": {
    "IVOSIDENIB": [
     "acute myeloid leukemia",
     "acute myeloid leukemia by FAB classification",
     "cholangiocarcinoma"
    ],
    "OLUTASIDENIB": [
     "acute myeloid leukemia by FAB classification",
     "acute myeloid leukemia"
    ],
    "VORASIDENIB": [
     "astrocytoma (excluding glioblastoma)",
     "oligodendroglioma",
     "glioma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  }
 ],
 "trials": {
  "by_antigen": {
   "PD-1": {
    "n": 33,
    "n_observational": 0,
    "n_active": 20,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04585750",
      "title": "The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)",
      "status": "RECRUITING",
      "last_update": "2026-09-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05482516",
      "title": "Evaluating Novel Therapies in ctDNA Positive GI Cancers",
      "status": "RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05732831",
      "title": "Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06270706",
      "title": "A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06282575",
      "title": "Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer",
      "status": "RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06423170",
      "title": "A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs",
      "status": "RECRUITING",
      "last_update": "2024-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06529718",
      "title": "Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients",
      "status": "RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06638931",
      "title": "Agnostic Therapy in Rare Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06852287",
      "title": "Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer",
      "status": "RECRUITING",
      "last_update": "2025-02-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07025174",
      "title": "Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer",
      "status": "RECRUITING",
      "last_update": "2025-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07334119",
      "title": "Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07726446",
      "title": "Study on Sequential Cryoablation, Relaforp Alpha, and Chemotherapy for Bile Duct Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02834013",
      "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03111732",
      "title": "Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)",
      "status": "COMPLETED",
      "last_update": "2021-12-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03260712",
      "title": "Pembrolizumab in Biliary Tract Cancer",
      "status": "COMPLETED",
      "last_update": "2023-11-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04003636",
      "title": "Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)",
      "status": "COMPLETED",
      "last_update": "2026-03-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04211168",
      "title": "Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers",
      "status": "UNKNOWN",
      "last_update": "2023-03-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04430738",
      "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04641871",
      "title": "Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-06-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04907851",
      "title": "A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)",
      "status": "COMPLETED",
      "last_update": "2025-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04924062",
      "title": "Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study",
      "status": "COMPLETED",
      "last_update": "2026-04-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05007106",
      "title": "MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)",
      "status": "COMPLETED",
      "last_update": "2025-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05009953",
      "title": "Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer",
      "status": "TERMINATED",
      "last_update": "2024-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05194072",
      "title": "A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-01-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05620498",
      "title": "Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.",
      "status": "UNKNOWN",
      "last_update": "2022-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05919095",
      "title": "A Clinical Study of a Preoperative Translational Therapy for Unresectable Gallbladder Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06134193",
      "title": "Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer",
      "status": "UNKNOWN",
      "last_update": "2023-11-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06178445",
      "title": "Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06717464",
      "title": "Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-12-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06963060",
      "title": "Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2025-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07269158",
      "title": "A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07623642",
      "title": "A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07765433",
      "title": "Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "PD-1",
     "pembrolizumab",
     "nivolumab",
     "tislelizumab",
     "toripalimab"
    ]
   },
   "PD-L1": {
    "n": 24,
    "n_observational": 0,
    "n_active": 13,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04585750",
      "title": "The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)",
      "status": "RECRUITING",
      "last_update": "2026-09-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05000294",
      "title": "Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types",
      "status": "RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05482516",
      "title": "Evaluating Novel Therapies in ctDNA Positive GI Cancers",
      "status": "RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06214572",
      "title": "Radiation Therapy in Unresectable Gall Bladder Cancer",
      "status": "RECRUITING",
      "last_update": "2025-04-11",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06282575",
      "title": "Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer",
      "status": "RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06591650",
      "title": "Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer",
      "status": "RECRUITING",
      "last_update": "2026-05-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07221253",
      "title": "A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)",
      "status": "RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07780838",
      "title": "Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03201458",
      "title": "Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer",
      "status": "COMPLETED",
      "last_update": "2024-04-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03257761",
      "title": "Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03267940",
      "title": "Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma",
      "status": "TERMINATED",
      "last_update": "2020-02-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03473574",
      "title": "Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients",
      "status": "COMPLETED",
      "last_update": "2023-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03833661",
      "title": "M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)",
      "status": "COMPLETED",
      "last_update": "2023-10-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03999658",
      "title": "A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies",
      "status": "WITHDRAWN",
      "last_update": "2023-05-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04066491",
      "title": "Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC",
      "status": "TERMINATED",
      "last_update": "2023-11-14",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04308174",
      "title": "Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04941287",
      "title": "Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-05-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05007106",
      "title": "MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)",
      "status": "COMPLETED",
      "last_update": "2025-08-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05239169",
      "title": "Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer",
      "status": "COMPLETED",
      "last_update": "2025-05-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05253053",
      "title": "To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-06-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05712356",
      "title": "A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-05-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06013943",
      "title": "Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC",
      "status": "UNKNOWN",
      "last_update": "2023-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07269158",
      "title": "A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07765433",
      "title": "Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "PD-L1",
     "durvalumab",
     "atezolizumab"
    ]
   },
   "HER2": {
    "n": 18,
    "n_observational": 2,
    "n_active": 8,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05786716",
      "title": "DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations",
      "status": "RECRUITING",
      "last_update": "2025-12-02",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06282575",
      "title": "Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer",
      "status": "RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06715839",
      "title": "Target-specific immunoPET Imaging of Digestive System Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-12-31",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06760819",
      "title": "A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07334119",
      "title": "Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-05-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07641036",
      "title": "Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004074",
      "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu",
      "status": "COMPLETED",
      "last_update": "2013-02-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005842",
      "title": "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2013-02-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00031681",
      "title": "7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)",
      "status": "COMPLETED",
      "last_update": "2013-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00478140",
      "title": "Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery",
      "status": "TERMINATED",
      "last_update": "2019-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02662348",
      "title": "T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System",
      "status": "UNKNOWN",
      "last_update": "2016-01-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02836847",
      "title": "Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2018-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03768375",
      "title": "Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2018-12-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03929666",
      "title": "A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-09-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04430738",
      "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04466891",
      "title": "A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers",
      "status": "COMPLETED",
      "last_update": "2025-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05194072",
      "title": "A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-01-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06178445",
      "title": "Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 1,
     "n_observational": 0,
     "n_active": 1,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT07641036",
       "title": "Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer",
       "status": "RECRUITING",
       "last_update": "2026-06-11",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "HER2",
     "ERBB2",
     "trastuzumab",
     "zanidatamab",
     "Ziihera",
     "trastuzumab deruxtecan",
     "Enhertu",
     "pertuzumab",
     "tucatinib"
    ]
   },
   "FGFR2": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07780838",
      "title": "Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "FGFR2",
     "pemigatinib",
     "futibatinib",
     "erdafitinib"
    ]
   },
   "IDH1": {
    "n": 0,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "IDH1",
     "ivosidenib"
    ]
   },
   "EGFR": {
    "n": 15,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06715839",
      "title": "Target-specific immunoPET Imaging of Digestive System Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-12-31",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06760819",
      "title": "A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00033462",
      "title": "Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer",
      "status": "COMPLETED",
      "last_update": "2013-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00266097",
      "title": "Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer",
      "status": "COMPLETED",
      "last_update": "2012-03-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00350753",
      "title": "Avastin and Tarceva for Upper Gastrointestinal Cancers",
      "status": "COMPLETED",
      "last_update": "2009-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00356889",
      "title": "Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors",
      "status": "COMPLETED",
      "last_update": "2014-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00397384",
      "title": "Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00832637",
      "title": "Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers",
      "status": "TERMINATED",
      "last_update": "2018-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00987766",
      "title": "Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer",
      "status": "COMPLETED",
      "last_update": "2017-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01093222",
      "title": "Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma",
      "status": "COMPLETED",
      "last_update": "2015-06-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01267344",
      "title": "A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC",
      "status": "COMPLETED",
      "last_update": "2016-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01308840",
      "title": "Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer",
      "status": "COMPLETED",
      "last_update": "2016-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01389414",
      "title": "Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX)Versus GEMOX Alone to Treat Advanced Biliary Tract Adenocarcinoma",
      "status": "COMPLETED",
      "last_update": "2015-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02836847",
      "title": "Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2018-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03768375",
      "title": "Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2018-12-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "EGFR",
     "erlotinib",
     "cetuximab",
     "panitumumab"
    ]
   },
   "CTLA-4": {
    "n": 4,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07025174",
      "title": "Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer",
      "status": "RECRUITING",
      "last_update": "2025-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02834013",
      "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03473574",
      "title": "Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients",
      "status": "COMPLETED",
      "last_update": "2023-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05239169",
      "title": "Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer",
      "status": "COMPLETED",
      "last_update": "2025-05-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "CTLA-4",
     "ipilimumab",
     "tremelimumab"
    ]
   },
   "Claudin 18.2": {
    "n": 0,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "claudin 18.2",
     "CLDN18.2",
     "zolbetuximab"
    ]
   }
  },
  "by_drug": {
   "AFATINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04183712",
      "title": "Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA",
      "status": "RECRUITING",
      "last_update": "2024-10-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AFATINIB DIMALEATE": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04183712",
      "title": "Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA",
      "status": "RECRUITING",
      "last_update": "2024-10-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CETUXIMAB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00397384",
      "title": "Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01267344",
      "title": "A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC",
      "status": "COMPLETED",
      "last_update": "2016-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02836847",
      "title": "Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2018-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03768375",
      "title": "Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2018-12-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "COPANLISIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02631590",
      "title": "Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma",
      "status": "COMPLETED",
      "last_update": "2021-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ERLOTINIB": {
    "n": 8,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00033462",
      "title": "Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer",
      "status": "COMPLETED",
      "last_update": "2013-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00266097",
      "title": "Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer",
      "status": "COMPLETED",
      "last_update": "2012-03-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00350753",
      "title": "Avastin and Tarceva for Upper Gastrointestinal Cancers",
      "status": "COMPLETED",
      "last_update": "2009-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00356889",
      "title": "Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors",
      "status": "COMPLETED",
      "last_update": "2014-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00397384",
      "title": "Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00832637",
      "title": "Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers",
      "status": "TERMINATED",
      "last_update": "2018-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00987766",
      "title": "Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer",
      "status": "COMPLETED",
      "last_update": "2017-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01093222",
      "title": "Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma",
      "status": "COMPLETED",
      "last_update": "2015-06-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "GEFITINIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02836847",
      "title": "Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2018-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03768375",
      "title": "Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2018-12-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LAPATINIB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00101036",
      "title": "Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2018-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00107536",
      "title": "Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer",
      "status": "COMPLETED",
      "last_update": "2015-04-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02836847",
      "title": "Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2018-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03768375",
      "title": "Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2018-12-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LAPATINIB DITOSYLATE": {
    "n": 4,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00101036",
      "title": "Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2018-04-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00107536",
      "title": "Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer",
      "status": "COMPLETED",
      "last_update": "2015-04-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02836847",
      "title": "Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2018-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03768375",
      "title": "Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2018-12-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PANITUMUMAB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01308840",
      "title": "Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer",
      "status": "COMPLETED",
      "last_update": "2016-08-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01389414",
      "title": "Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX)Versus GEMOX Alone to Treat Advanced Biliary Tract Adenocarcinoma",
      "status": "COMPLETED",
      "last_update": "2015-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PEMIGATINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07780838",
      "title": "Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PERTUZUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05786716",
      "title": "DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations",
      "status": "RECRUITING",
      "last_update": "2025-12-02",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "REGORAFENIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02053376",
      "title": "A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy",
      "status": "COMPLETED",
      "last_update": "2019-01-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02115542",
      "title": "Single Agent Regorafenib in Refractory Advanced Biliary Cancers",
      "status": "COMPLETED",
      "last_update": "2021-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SERIBANTUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04383210",
      "title": "Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-04-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TRASTUZUMAB": {
    "n": 8,
    "n_observational": 1,
    "n_active": 3,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05786716",
      "title": "DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations",
      "status": "RECRUITING",
      "last_update": "2025-12-02",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004074",
      "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu",
      "status": "COMPLETED",
      "last_update": "2013-02-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005842",
      "title": "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2013-02-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00478140",
      "title": "Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery",
      "status": "TERMINATED",
      "last_update": "2019-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02836847",
      "title": "Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2018-05-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03768375",
      "title": "Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2018-12-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04430738",
      "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06178445",
      "title": "Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TRASTUZUMAB DERUXTECAN": {
    "n": 0,
    "n_observational": 1,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": []
   },
   "TUCATINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04430738",
      "title": "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VANDETANIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00753675",
      "title": "Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer",
      "status": "COMPLETED",
      "last_update": "2016-10-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VARLITINIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03093870",
      "title": "Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer",
      "status": "COMPLETED",
      "last_update": "2021-08-03",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03231176",
      "title": "Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer",
      "status": "COMPLETED",
      "last_update": "2020-11-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ZANIDATAMAB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06282575",
      "title": "Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer",
      "status": "RECRUITING",
      "last_update": "2026-09-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03929666",
      "title": "A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2025-09-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04466891",
      "title": "A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers",
      "status": "COMPLETED",
      "last_update": "2025-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   }
  }
 }
}